Cite
A novel STING agonist for cancer immunotherapy and a SARS-CoV-2 vaccine adjuvant.
MLA
Wu, Jun-Jun, et al. “A Novel STING Agonist for Cancer Immunotherapy and a SARS-CoV-2 Vaccine Adjuvant.” Chemical Communications, vol. 57, no. 4, Jan. 2021, pp. 504–07. EBSCOhost, https://doi.org/10.1039/d0cc06959k.
APA
Wu, J.-J., Zhao, L., Han, B.-B., Hu, H.-G., Zhang, B.-D., Li, W.-H., Chen, Y.-X., & Li, Y.-M. (2021). A novel STING agonist for cancer immunotherapy and a SARS-CoV-2 vaccine adjuvant. Chemical Communications, 57(4), 504–507. https://doi.org/10.1039/d0cc06959k
Chicago
Wu, Jun-Jun, Lang Zhao, Bei-Bei Han, Hong-Guo Hu, Bo-Dou Zhang, Wen-Hao Li, Yong-Xiang Chen, and Yan-Mei Li. 2021. “A Novel STING Agonist for Cancer Immunotherapy and a SARS-CoV-2 Vaccine Adjuvant.” Chemical Communications 57 (4): 504–7. doi:10.1039/d0cc06959k.